Duopharma Biotech Berhad announced that it has secured a government contract valued at approximately RM65.08 million to supply recombinant human insulin formulations to the Ministry of Health (MOH).
The pharmaceutical group said its wholly owned subsidiary together with manufacturer Biocon Sdn. Bhd., had received and accepted a Letter of Award from the government on Feb 16, 2026.
Under the agreement, Biocon will manufacture the insulin products while Duopharma Marketing will act as the appointed distributor responsible for delivering the products to the Ministry of Health.
The contract, awarded via direct negotiation, will remain in force until May 15, 2026, with a total estimated value of RM65.08 million.
Biocon Sdn. Bhd., a subsidiary of Biocon Biologics, operates one of Asia’s largest integrated insulin manufacturing facilities located in BioXcell biotechnology park in Iskandar Puteri, Johor.
The facility, built with an investment exceeding US$600 million, manufactures recombinant human insulin and insulin analogues for both domestic and global markets. It has received regulatory approvals from several international agencies, including Malaysia’s National Pharmaceutical Regulatory Agency, Ireland’s Health Products Regulatory Authority, and the US Food and Drug Administration.
